Equitec Specialists’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Equitec Specialists’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-36,400	Closed	-$789K	–	136
2015 Q4	$789K	Sell	36,400 -1,300	-3%	-$25.3K	0.28%	41
2015 Q3	$747K	Hold	37,700	–	–	0.32%	40
2015 Q2	$1.31M	Buy	37,700 +25,228	+202%	+$770K	0.34%	39
2015 Q1	$324K	Buy	+12,472	New	+$229K	0.09%	54

Other funds holding HZNP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Equitec Specialists's HZNP Position: Q1 2016 in Review

Equitec Specialists sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2016, closing a stake of 36,400 shares — an estimated $789K sold.

Equitec Specialists first reported a position in HZNP in Q1 2015 and held it in 4 quarters. The position peaked at $1.31M in Q2 2015. 196 funds tracked by Wall St. Rank hold HZNP as of Q1 2016.

Equitec Specialists reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2016 after selling out during the quarter.
Equitec Specialists sold 36,400 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2016, an estimated $789K.
Equitec Specialists first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 4 quarters.
Equitec Specialists's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.31M in Q2 2015.
196 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2016.

Based on Equitec Specialists's 13F filing for Q1 2016, filed 29 Apr 2016.